Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

Core Viewpoint - Mangoceuticals, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.5 million to support its health and wellness product development and operations [1][3]. Group 1: Offering Details - The transactions involved the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant to purchase one share of Common Stock at an exercise price of $1.4245 [2]. - The offering price per Common Unit was set at $1.295, while the Pre-Funded Unit was priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Aspects - Aegis Capital Corp. served as the exclusive placement agent for the offerings, and the registered direct offering was conducted under an effective shelf registration statement previously filed with the SEC [4]. - The securities sold in the private placement were not registered under the Securities Act and were offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing a range of men's health and wellness products through a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7].